Lv1
70 积分 2025-12-12 加入
LEAP2 as a therapeutic target in obesity and cardiometabolic disorders
14天前
已完结
Analog of prolactin-releasing peptide reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia
22天前
已完结
Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to watch
25天前
已完结
The evolving landscape of obesity pharmacotherapy
1个月前
已完结
中国高尿酸血症与痛风诊疗指南(2024)第一部分：对一般痛风患者的建议
1个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
2个月前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2个月前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
2个月前
已完结
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
2个月前
已完结
皖公网安备34019202002308
